News | News By Subject | News by Disease News By Date | Search News

Psoriasis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
A Look at Amgen (AMGN) and Its $10 Billion Flop Onyx (AMGN)     11/3/2016
This Experimental Drug Could be Johnson & Johnson (JNJ)'s Next Blockbuster     10/7/2016
Sun Pharma (SUNPHARMA.NS), Almirall in $50 Million Psoriasis Drug Tie-Up     7/28/2016
FDA Panel Says Valeant (VRX)'s Psoriasis Med Should be Approved with Risk Plan     7/20/2016
FDA Panel Divided on Valeant (VRX)'s Psoriasis Drug Suicide Risk     7/18/2016
AbbVie (ABBV) Shows Off Positive HUMIRA Phase III Data in Moderate to Severe Fingernail Psoriasis     7/7/2016
Bay Area's XenoPort (XNPT) Snags Psoriasis and MS Deal Worth $490 Million+ from Dr. Reddy's Laboratories Ltd. (RDY)     3/28/2016
Eli Lilly (LLY) Wins FDA Approval for Psoriasis Drug Taltz     3/23/2016
Samsung Bioepis, Biogen (BIIB) Biosimilar is About to Take a Huge Chunk of Pfizer (PFE)'s Profits     11/20/2015
FDA Rejects Expanded Approval of Pfizer (PFE)'s Arthritis Drug Xeljanz     10/15/2015
Top 10 Best-Selling Biotech Drugs     10/2/2015
XenoPort (XNPT)'s Shares Jump After Psoriasis Treatment Meets Phase II Primary Endpoint     9/15/2015
AstraZeneca PLC (AZN) Inks $445 Million Psoriasis Drug Pact With Valeant (VRX) After Amgen (AMGN) Bows Out     9/2/2015
Exciting Time for Biotech in New Jersey     6/29/2015
Amgen (AMGN) Dumps AstraZeneca PLC (AZN) Pact After Patients Developed Suicidal Thoughts     5/27/2015

News from Around the Web
Why FDA Delay on Brodalumab is Actually Great News For Valeant (VRX)     11/30/2016
MorphoSys AG Moves Closer To Getting First Antibody Drug On Market     10/3/2016
Family History Biggest Predictor Of Heart Attacks In People With Psoriasis, University of Copenhagen Study     7/1/2016
Being Fat Ups Your Risk Of Getting This Skin Disease, University of Copenhagen Study     5/2/2016
Why It Feels So Good To Scratch An Itch, Published In Proceedings Of The Entomological Society Of Washington     2/29/2016
New Treatment for Psoriasis? Norwegian University of Science and Technology Study     1/14/2013
Analysis Links Psoriasis, Diabetes, University of California, Davis (UCD) Study     10/18/2012
Vigorous Exercise Might Keep Psoriasis at Bay, Brigham and Women's Hospital Study     5/22/2012
No Major Heart Risk Seen in New Psoriasis Drugs, Baylor Research Institute Study     8/24/2011
Study Sees Link Between Psoriasis, Obesity in Kids, Kaiser Permanente Reveals     5/23/2011
Antibody Efficacious in Psoriasis of the Hands and Feet, Central Dermatology Study     12/22/2010
Alcohol Linked to Psoriasis in Women, Harvard University Study     12/21/2010
NonLight Beer Consumption Linked to Psoriasis in Women, Brigham and Women's Hospital Study     8/17/2010
Psoriasis Linked To Higher Depression, Anxiety And Suicidal Feelings Risk, University of Pennsylvania Study     8/17/2010
Gene Variation Is 'Major Genetic Determinant Of Psoriasis', University of Utah Study     8/28/2009

Press Releases
FDA Clears Valeant (VRX)'s New Psoriasis Drug, But With Strings Attached     2/16/2017
Dermira (DERM), UCB Group (UCBJF.PK) Release: Companies' Psoriasis Drug Wows In Phase III Study, Eyes Q3 Filing     1/19/2017
Valeant (VRX) Release: Pharma Company Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118     1/10/2017
Janssen Biotech (JNJ) Submits Application Seeking FDA Approval Of STELARA (Ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis     12/16/2016
Valeant (VRX) Announces Phase 3 Results For Psoriasis Treatment IDP-118     12/8/2016
Dermira (DERM) Release: Second CIMZIA (Certolizumab Pegol) Phase III Trial Meets Co-Primary Efficacy Endpoints In Patients With Moderate-To-Severe Chronic Plaque Psoriasis     12/8/2016
Lycera Announces Initiation Of Phase 2 UPRISE Clinical Trial Of LYC-30937-EC For Patients With Moderate Psoriasis     12/7/2016
Janssen Biotech (JNJ) Submits Application To FDA Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis     11/17/2016
MorphoSys AG Announces That Its Licensee Janssen Has Presented Positive Clinical Data Of Guselkumab In Psoriatic Arthritis     11/15/2016
Merus (MRUS) Receives €1.5 Million EUREKA Eurostars Grant With Aquila BioMedical To Jointly Develop Immunological Assays For Identification Of Novel Immunomodulatory Bispecific Antibodies     11/9/2016
Amgen (AMGN) Release: FDA Approves Expanded Use Of ENBREL (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis     11/7/2016
Supportive Data For The Use Of Santalis' East Indian Sandalwood Oil (EISO) For The Treatment Of Psoriasis Is Presented At International Conference     11/4/2016
Can-Fite BioPharma (CFBI) Advances Towards A Pivotal Phase III Clinical Trial In Psoriasis With Piclidenoson (CF101) Following Reaching Agreement With EMA     11/1/2016
Celgene (CELG) Release: Oral OTEZLA (Apremilast) Receives Positive Nice Recommendation For Adults With Chronic Plaque Psoriasis     10/20/2016
Pfizer (PFE) to Launch Cheaper Version of Johnson & Johnson (JNJ)'s Remicade in November     10/18/2016